Angiogenesis Modulations in Health and Disease
Practical Applications of Pro- and Anti-angiogenesis Targets
1st Edition
Published on 25. May 2013
Book
Hardback
X, 206 pages
978-94-007-6466-8 (ISBN)
Description
This book is a major update of novel targets in angiogenesis modulation, including pro- and anti-angiogenesis. There is in-depth coverage of preclinical and clinical methods and models, investigational status, and clinical applications. The impact of nanotechnology in advancing the applications of pro-and anti-angiogenesis strategies is also highlighted, along with stem cell and biotechnologies in research and development of angiogenesis modulating targets.
More details
Language
English
Place of publication
Dordrecht
Netherlands
Target group
Primary & secondary/elementary & high school
Graduate
Illustrations
X, 206 p.
Dimensions
Height: 241 mm
Width: 160 mm
Thickness: 17 mm
Weight
494 gr
ISBN-13
978-94-007-6466-8 (9789400764668)
DOI
10.1007/978-94-007-6467-5
Schweitzer Classification
Other editions
Additional editions
Shaker A. Mousa | Paul J. Davis
Angiogenesis Modulations in Health and Disease
Practical Applications of Pro- and Anti-angiogenesis Targets
Book
06/2015
Springer
€160.49
Shipment within 15-20 days
Shaker A. Mousa | Paul J. Davis
Angiogenesis Modulations in Health and Disease
Practical Applications of Pro- and Anti-angiogenesis Targets
E-Book
07/2014
1st Edition
Springer
€149.79
Available for download
Content
Preface.- Angiogenesis assays: an appraisal of current techniques.- Survey of pro-angiogenesis strategies.- Angiogenesis modulation by arachidonic acid - derived lipids: positive and negative regulators of angiogenesis.- Pro-angiogenic activity of thyroid hormone analogues: Mechanisms, physiology and clinical prospects.- Actions of steroids and peptide hormones on angiogenesis.- Role of non-neuronal nicotinic acetylcholine receptors in angiogenesis modulation.- Catecholamine neurotransmitters: an angiogenic switch in the tumor microenvironment.- Impact of nanotechnology on therapeutic angiogenesis.- Survey of anti-angiogenesis strategies.- Tetraiodothyroacetic acid (tetrac), nanotetrac and anti-Angiogenesis.- Integrin antagonists and angiogenesis.- Anti-angiogenesis therapy as an adjunct to chemotherapy in oncology.- Anti-vegf strategies in ocular angiogenesis- mediated disorders, with special emphasis on age-related macular degeneration.- Application of nanotechnology to targeting tumor angiogenesis for therapeutic benefit.- Biomarkers of response and resistance to anti-angiogenic treatment.- Speculations on new directions in which angiogenesis may proceed. Index.